GeNO, a privately held technology company, has hired four new senior executives and promoted two others, more than doubling its executive management team.
New hires to the executive management team are:
Kurt Dasse, Ph.D., former president and founder of recently-sold Levitronix, was named executive vice president of GeNO. Dasse has spent nearly three decades conducting research in cardiovascular disorders and developing and commercializing medical devices. He has written more than 100 journal articles and multiple book chapters, and holds several patents.
Jack Whiting, former vice president, general counsel of Levitronix, will serve as vice president of operations. Whiting will be responsible for finance, legal, human resources and risk management functions, as well as supply chain management.
Daniel O'Donnell, former vice president, business development at L-3 CyTerra was appointed general manager. O'Donnell will be responsible for managing daily operations and new R&D business pursuits.
Ed Bromberg, Ph.D., previously at L-3 CyTerra and Thermo, will serve as R&D manager. Bromberg brings more than 34 years of experience in the development of scientific instrumentation from concept to release to production.
Promoted members of the executive management team are:
Robert Roscigno, Ph.D., was promoted to executive vice president. Roscigno has a unique combination of clinical development, sales, marketing and business expertise in the pharmaceutical industry, with over 16 years of drug development experience.
Lucas Gamero, Ph.D., was promoted to vice president of R&D. Gamero has 15 years of experience in research and new product development in the medical device and pharmaceutical industry.